Mechanism of Nardostachyos Radix et Rhizoma (NRER)-Salidroside in the Treatment of Premature Ventricular Beats Based on Network Pharmacology and Molecular Docking

Abstract

Objective To analyse the mechanism of NRER-Salidroside in the treatment of premature ventricular tachycardia by using network pharmacology and molecular docking and to provide the basis for developing the use of clinical traditional Chinese medicine. Method The chemical compositions of NRER and salidroside were determined, and their related targets were predicted. The disease-related targets were obtained by searching the common disease databases Genecards, OMIM and TTD, and the intersection between the predicted targets and the disease targets was determined. Then, the STRING database was used to set up a network of protein‒protein interactions (PPIs) between NRER and salidroside and the common targets of PVB and establish a network of PPIs. Result Forty-one active components of NRSR-Salidroside were detected, with 420 potential targets of action, with a total of 1688 PVB targets, and the top 10 core targets of drug-disease degree values were AKT1, TNF, GAPDH, SRC, PPARG, EGFR, PTGS2, ESR1, MMP9, and STAT3. KEGG analysis indicated that its mechanism may be related to the calcium signalling pathway, cancer signalling pathway, AGE-RAGE signalling pathway and other pathways. Molecular docking suggested that most of the active ingredients of the NRSR-salidroside pairs were well bound to the core targets. Conclusion Based on novel network pharmacology and molecular docking validation research methods, we revealed for the first time the potential mechanism of salidroside in PVB therapy.